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Abstract: Phosphatidylinositol (P1) 3-kinase is activated
by a variety of agents, including various growth factors,
and has been proposed to play a role in initiation of cell
growth, proliferation, and differentiation. We here investi-
gate the effect of various membrane lipids on P1 3-kinase
immunopurified from human SH-SY5Y neuroblastoma
cells. CDP-diacylglycerol (CDP-DAG) inhibited Fl 3-ki-
nase activity with an lC~~of 6 ~tM. Phosphatidate (PA)
was also inhibitory (1050 = 38
1iM) as was lysophosphati-
date. Neither DAG nor any of the other phospholipids
examined affected P1 3-kinase activity. The results offer
the possibility that CDP-DAG or PA at critical membrane
sites may exert functionally significant metabolic regula-
tion at the point of convergence of the P1 3-kinase—di-
rected and the P1 4-kinase—directed phosphoinositide
signal transduction pathways. Key Words: Phosphatidyl-
inositol 3-kinase—CDP-diacylglycerol—Lysophosphati-
date—Phosphatidate—SH-SY5Y neuroblastoma cells.
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The SH-SY5Y human neuroblastoma cell line
(Pahlman et al., 1990) has proven useful for studying
the ligand-stimulated receptor-mediated cleavage of
phosphatidylinositol 4,5-bisphosphate [Ptdlns (4,5) P2
P1(4,5)P2] into the two chemical second messengers
diacyiglycerol (DAG) and D-myo-inositol I ,4,5-tris-
phosphate [1(1,4,5 )P1] (Fisher et al., 1992). This sub-
clone is enriched in muscarinic cholinergic receptors
and has served as a model system for studies on physio-
logical regulation of the phosphoinositide signal trans-
duction system and of intervention by neuropharmaco-
logical agents (Gray et al., 1994). Resynthesis of
PI(4,5)P2 proceeds via phosphorylation of DAG by
DAG-kinase and conversion of the resulting phosphati-
date (PtdOH; PA) to cytidine diphosphodiacylglycerol
(CDP-DAG), which serves, in turn, together with mo-
sitol, as a cosubstrate of PT synthase. For the newly
formed phosphatidylinositol (P1) to reenter the signal
transduction pathway requires that it be phosphory-
lated sequentially, first at the 4’ position of inositol,
to form phosphatidylinositol 4-phosphate (PI4P), then
at the 5’ position to form Pl(4,5)P2. Over the past
few years, an alternate fate of PT has been described
in which P1 3-kinase acts on P1 to produce phosphati-
dylinositol 3-phosphate (PI3P) (Whitman et al., 1988;
Carpenter and Cantley, 1990; Panayotou and Wa-
terfleld, 1992; Parker and Waterfield, 1992; Carter and
Downes, 1993; Stephens et al., 1993). This isomeric
phosphatidylinositol phosphate (PIP), as well as phos-
phatidylinositol 3,4-bisphosphate [P1(3,4) P2] and
phosphatidylinositol 3,4,5-trisphosphate [P1(3,4,5) Pa],
termed collectively the “3’-phosphoinositides,” have
been identified in various tissues and cultured cells in
association with growth and differentiation, e.g., after
the addition to media of various growth factors (Parker
and Waterfield, 1992). There is evidence that intact
3 ‘-phosphoinositides are chemical messengers (Na-
kanishi et al., 1993; Stephens et al., 1993; Toker et al.,
1994), although it remains possible that there are as
yet unidentified cleavage products that mediate signal
transduction via this pathway. Although it is likely that
some 3-phosphoesterification occurs directly on PI4P
and on PI(4,5)P2, the phosphorylation of P1 by either
P1 3- or 4-kinase would appear to constitute a meta-
bolic branch point, the regulation of which could affect
either or both of the pathways. We have established
the presence of P1 3-kinase activity in SH-SY5Y
cells, as well as its modification by CDP-DAG and
by PA, and raise the possibility that regulatory feed-
back occurs in inositol lipid—mediated signal trans-
duction.
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EXPERIMENTAL PROCEDURES
Materials
ATP, phospholipids (unless otherwise specified), CMP,
CDP, CTP, CDP-glycerol, and bovine serum albumin were
purchased from Sigma Chemical (St. Louis, MO, U.S.A.).
Stearoylarachidonoyl-CDP-DAG was a generous gift of
A. K. Hajra. CDP-DAG (from egg lecithin) was from Ser-
dary Research (London, Ontario, Canada). Cardiolipin was
the product of Avanti Polar Lipids (Alabaster, AL, U.S.A.).
iy-~2P]ATP(3,000 Ci/rnmol) was from Du Pont-NEN(Wilmington, DE, U.S.A.). Silica gel 60 TLC plates were
from Merck (Darmstadt, Germany). Dulbecco’s modified
Eagle’s medium (DMEM), fetal bovine serum (FBS), and
protein A-agarose were purchased from GibcoBRL (Gaith-
ersburg, MD, U.S.A.). Anti-p85 antiserum was from Upstate
Biotechnology Incorporated (Lake Placid, NY, U.S.A.). SH-
SY5Y cells (60—80 passages) were grown to confluency
and treated as described herein.
Preparation of P1 3-kinase
P1 3-kinase was prepared from confluent SH-SY5Y cells
grown in DMEM supplemented with 10% FBS at 37CC in a
humidified atmosphere of 10% CO
2. Cells, grown in 150-
mm culture dishes, were washed twice with 15 ml of phos-
phate-buffered saline (PBS), pH 7.4, aspirated, and lysed
with 2 mI/dish of lysis buffer containing 137 mM NaCI, 20
mM Tris-HCI (pH 8.0), 1 mM EDTA, 1 mM MgCI2, 1
mM CaCI2, 10% glycerol, 1% Nonidet P-40 (NP-40), 10
pg/mI leupeptin, 2 pg/ml aprotinin, 1 mM phenylmethylsul-
fonyl fluoride, and 1 mM sodium orthovanadate. The cells
were scraped free from the dishes and centrifuged at 6,000
g for 10 mm. The resulting supernatant was incubated in 50-
ml conical plastic tissue-culture tubes with shaking overnight
with 4 pg of anti-p85 antiserum per milligram of protein,
after whichprotein A-agarose beads were added for 2 h with
mixing. Immune complexes bound to the beads were washed
three times with PBS containing 1% NP-40, twice with PBS
containing 0.5 M LiCI and 0.1 M Tris-HCI (pH 7.5), and
twice with 0.1 M NaCI containing 1 mM EDTA and 10mM
Tris-HCI (pH 7.5).
P1 3-kinase assay
The reaction mixture for measuring P1 3-kinase activity
contained 50 p1 of the immunoprecipitated enzyme prepara-
tion (representing enzyme from 5 x 10~’cells) and 50 pl of
P1 micelles that were prepared by sonicating 800 pg of P1
(Sigma, from bovine liver) in 1 ml of20 mM HEPES buffer
(pH 7.6)containing I mMEDTA for 45 s (Kontes sonicator
with a microtip probe). Fifty microliters of HEPES buffer
or various sonicated lipids to be tested were added at this
poinl. The mixture was preincubated for 15 mm at room
temperature. and the reaction was started by addition of 50
p1 of 20 mM MgCI2 containing 150 pM [y-
32P]ATP (2
Ci per assay). The reactio was terminated after 10 mm
by the addition of 200 p,1 of 1 M methanolic HCI followed
by 200 pl of chloroform. The resulting organic phase was
dried, resuspended in 25 pl of chloroform/methanol (1:1),
and spotted on a TLC plate that was precoated with I %
potassium oxalate. The plate was developed in chloroform!
methanol/H
20/7.7 M ammonium hydroxide (60:47:11.3:2)
(Serunian et al., 1991).
32P-labeled PI3P was visualized by
autoradiography and compared with an iodine-stained au-
thentic PI4P standard. Radioactivity in PI3P wasquantitated
by liquid scintillation spectrometry.
FIG. 1. Immunoblot and enzymatic activity of P1 3-kinase iso-
lated from SH-SY5Y cells with p85 anti-sera. A: Fl 3-kinase was
immunoprecipitated from SH-SY5Y cells, as described in Experi-
mental Procedures, and immunoblotted after SDS-PAGE, using
either preimmune rabbit anti-serum (Pre.l.) or anti-p85 anti-se-
rum (a-p85). The prominent spots above the 45-kDa mark repre-
sent lgG. B: The immunoprecipitates were assayed for P1 3-
kinase activity as described in the text. Lane 1, preimmuneserum
immunoprecipitates; lane 2, ct-p85 immunoprecipitates; lane 3,
cs-p85 + 0.5% NP-40; lane 4, a-p85 + 50 nM WT. The data
shown are representative of three independent experiments,
which gave similar results.
Immunoblotting of the p85 subunit of P1 3-kinase
Cells were lysed, followed by immunoprecipitation with
anti-p85 antiserum as described. After washing, immune
complexes were resolved on 10% sodium dodecyl sulfate—
polyacrylamide gel electrophoresis (SDS-PAGE). Separated
proteins were transferred to nitrocellulose paper and ana-
lyzed for the presence of p85 by protein immunoblot using
anti-p85 antiserum. Bound antibodies were visualized by an
enhanced chemiluminescence (ECL) detection system, us-
ing horseradish peroxidase conjugated to anti-rabbit lgG as
the secondary antibody (Amersham, Arlington. Heights, IL.
U.S.A.).
RESULTS
Assay of P1 3-kinase
Human SH-SY5Y neuroblastoma cells were found
to be a ready source of P1 3-kinase. The presence of
the p85 protein in anti-p85 immunoprecipitates from
these cells was confirmed by western blotting with the
same antiserum and detection by ECL (Fig. IA). A
major band at the 85-kDa region was visualized in
the anti-p85 antiserum immunoprecipitates and not in
those prepared with preimmune rabbit serum. PT is the
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FIG. 2. Effect of various lipids on P1 3-kinase activity. P1 3-kinase
activity was measured under standard assayconditions with 200
pM Fl and 50 pM labeled ATP in the absence and presence of
100 pM concentrations of the indicated lipids. The data shown
are representative of three independent experiments that gave
similar results. Control value of [
32P]PI3P was 6,298 it 518 cpm.
Con, control; CDP-DAG1, egg PC—derived CDP-DAG; CDP-
DAG2, stearoylarachidonoyl-CDP-DAG; FE, phosphatidyletha-
nolamine; PS, phosphatidylserine; Car, cardiolipin; DAG1, dio-
leoylacylglycerol; DAG2, stearoylarachidonoyl-DAG.
major intracellular substrate for P1 3-kinase (Berggren
et al., 1993) and was thereft)re used for these studies.
Optimum incubation conditions were those described
by Serunian et al. (1991); phosphorylation in SH-
SY5Y cells was found to be linear with time and en-
zyme concentration (not shown). As indicated in Fig.
1B, P1 phosphorylation to PIP was detected in the anti-
p85 immunoprecipitates but not in preimmune rabbit
serum immunoprecipitates. To examine the possible
presence of P1 4-kinase activity in the preparations,
we performed the phosphorylation reaction in the pres-
ence of NP-40, a detergent known to inhibit P1 3-
kinase activity and to stimulate P1 4-kinase activity
(Carpenter and Cantley, 1990). Addition of 0.5% NP-
40 to the reaction mixture inhibited the formation of
32P-Iabeled lipid completely, indicating the absence of
detectable P1 4-kinase activity in the preparation. Fur-
thermore, we found that wortmannin (WT) inhibited
the phosphorylation of P1 in our preparation com-
pletely (Fig. IB). WT is found in a variety of fungi
and has been shown to selectively block P1 3-kinase
activity in vitro and in vivo by binding covalently to the
I lO-kDa subunit of P1 3-kinase (Powis et al., 1994).
Effect of various lipids on P1 3-kinase activity
Membrane-bound enzymes, especially those that
mediate membrane lipid metabolism are generally
known to be responsive to their lipid environment
(Hjelmstad and Bell, 1991). We therefore examined
the effect of various membrane lipids on P1 3-kinase
activity in vitro at saturating concentrations of Mg2~,
ATP, and P1. As shown in Fig. 2, egg phosphatidylcho-
line (PC)-derived CDP-DAG and stearoyl-arachido-
noyl-CDP-DAG produced 93 and 88% inhibition of
PI3P formation, respectively. The observed block by
CDP-DAG, therefore, does not appear to be highly
selective with regard to the fatty acid composition of
the molecule. CDP-glycerol, the deacylated form of
CDP-DAG, had no effect on P1 3-kinase activity (see
Table I), indicating that fatty acyl substituents are
required for the inhibitory effect. Lyso-CDP-DAG was
not tested. P1 3-kinase activity was also inhibited, al-
beit to a lesser extent (59%), by PA. l-Oleoyl-sn-
glycero-3-P (lyso-PA; LPA) inhibited P1 3-kinase to
the same extent as PA (t = 0.4, NS), whereas lyso-
PC was ineffective. None of the other phospholipids
examined, i.e., PC, phosphatidylethanolamine, phos-
phatidylserine, or cardiolipin, significantly affected P1
3-kinase activity, nor did either of two species of
DAG used in this study, dioleoylglycerol or stearoyl-
arachidonoyldiacylglycerol (also see Fig. 3B).
Characterization of the inhibitory effect of
CDP-DAG on P1 3-kinase
The concentration dependence of the inhibition of
P1 3-kinase activity by CDP-DAG and PA is evident
in an autoradiogram made after TLC separation of
phosphorylated P1 lipids from P1 3-kinase assays,
which contain the inhibitory lipids (Fig. 3A). The plots
in Fig. 3B demonstrate that CDP-DAG and PA inhibit
P1 3-kinase in a dose-dependent manner, with esti-
mated lC
5~values of 6 and 38 pM, respectively.
Because of the unique structure of CDP-DAG, we
investigated the possibility that separate nucleotide-
and lipid-binding sites, acting together, might explain
the liponucleotide’s blocking action. By adding various
moieties of CDP-DAG alone or together, we estab-
lished that the intact molecule is required for inhibition.
TABLE 1. The effect of CDI’-DAG and related
compounds on J~P]PI3P formation
Lipid added PI3P formed (cpm) % of inhihititm
None 6.759 © 583 0
CDP-DAG 830 © 69 88 © 8
PA 2.430 © 137 64 © 6
CMP 6,408 ~- 231 5 ±4
PA +CMP 2.651 ~ 302 61±II
DAG 6,709 it 159 1 ~ 2
CDP 6.883 ~i 531 0
DAG + CI)P 6.847 ~ 885 0
CTP 5.872 it 398 13 it 7
CDP-glycerol 6.651 ±729 2 it II
P1 3—kinase activity in anti-PI 3-kinase antibody immunoprecipi-
tates from SH-SY5Y cells was measured as the [
2P]ATP-de endent
phosphorylation of Pt. as described in Experimental Procedures. The
indicated compounds were added at a concentration of 100 pM for
It) mm of incubation. Results are expressed as percentages of inhibi-
tion of PI3P formed in the reaction and represent mean ~ SD (half
the range) values of duplicate determinations, and are typical of
three experiments.
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FIG. 3. Inhibition of P1 3-kinase activity by CDP-DAG and PA.
Fl 3-kinase was assayed in the presence of the indicated con-
centrations of egg PC—derived CDP-DAG (closed circles), PA
(open circles), or DAG (triangles). The phosphorylated lipid
productswere separated by TLC and then subjected toautoradi-
ography (A). The corresponding PIP bands were scraped and
counted. The P1 3-kinase activity is plotted (B) as the percentage
of uninhibited kinase activity (5,791 ±451 cpm; 100%).
Neither cytidine mono-, di-, nor triphosphate altered
P1 3-kinase activity (Table 1). Addition of PA and
CMP together produced inhibition similar to that
caused by PA alone, and the combination of DAG plus
CDP had no effect, confirming that the inhibitory effect
of CDP-DAG requires the intact liponucleotide mole-
cule. To examine the nature of the inhibition further,
we determined whether the effect of CDP-DAG could
be reversed by the addition of various concentrations
of the substrate P1 or ATP. As shown in Table 2, even
with concentrations of P1 and/or ATP five to 10 times
higher than were routinely used, the degree of inhibi-
tion was unaffected. Although we did not examine
these effects at other CDP-DAG concentrations, it does
not appear likely that CDP-DAG is a competitive in-
hibitor with respect to P1 or ATP.
DISCUSSION
Demonstration of the presence of P1 3-kinase in SH-
SYSY neuroblastoma cells and its inhibition by two
endogenous classes of lipids was made possible by
the availability of a high-affinity anti-p85 (regulatory
subunit) antibody that permitted us to immunopurify
an enzyme complex that also contained the 1 l0-kDa
catalytic subunit of PT 3-kinase. The isolated protein
complex phosphorylated P1 to a product that migrated
on TLC to a region predicted for PIPs. Although PI3P
and PI4P are not easily separable, the conclusion that
the product was solely PI3P was also supported by the
complete block of phosphorylation in the presence of
WT, an agent known to block selectively P1 3-kinase
but not P1 4-kinase. The result also indicated that there
was no detectable activity for arecently described WT-
insensitive P1-specific P1 kinase (Stephens et al.. 1994)
in these cells.
Although the inhibitory effect of CDP-DAG does
not appear to be restricted to a specific species of the
liponucleotide, fatty acylation of the glycerol moiety
is essential for the inhibitory action, as is the CDP
head group, because CDP-glycerol and DAG are with-
out effect, whereas inhibition, albeit to a lesser extent,
is observed with PA. The block by PA is in agreement
with aprevious report (Carpenter et al., 1990) in which
purified P1 3-kinase from rat liver was shown to be
inhibited 50% by 10 p.M PA. LPA was equally effec-
tive, as has been observed with other cellular actions
of PA and LPA such as their mitogenic actions
(Moolenaar, 1995). Recent studies indicate that LPA
can activate PT 3-kinase (Kumagai et al.. 1993; Moole-
naar, 1995). The stimulatory effect is distinct from the
present report of an inhibitory action of LPA in that
the former is mediated by its receptor and a G protein—
linked signal transduction cascade, whereas the latter
is the direct action of LPA on P1 3-kinase. Inhibition
of P1 3-kinase by CDP-DAG has not been reported
previously, although its block of P1 4-kinase has been
observed in yeast, as discussed herein. Both CDP-DAG
and PA are negatively charged phospholipids, and the
mechanism of the observed inhibition might therefore
be attributed to their negative charge. However, phos-
phatidylserine and cardiolipin, which are also nega-
tively charged, had no effect on P1 3-kinase activity.
Although it remains possible that a negative charge on
inhibitory lipids is necessary, it does not appear to be
TABLE 2. Efject.v of AlP and P1 on the
inhibitory ac/ion of CDP-DA G
Pt (p.M) ATP (pM) P1 3-kinase activity (r/r)
40 50 16.1 it 4.3
8t) 50 19.1 ± 3.2
200 5t) 13.0 ±1.5
1,000 50 15.4 it ((.9
20t) 5 17.8 ±3.7
200 SOt) 8.7 i- 3.1
P1 3—kinase activity in anti—PI 3—kinase antibody immunoprecipi—
tates was assayed in the presence of the indicated concentratIons of
P1, ATP, and 5t) pM CDP-DAG. The assay was started by adding
the enzyme, allowing equal opportunity for the inhibitor and the
competing substrates to bind. The determined lipid kinase activity
is given as a percentage of the uninhibited (tiiinmts L’DP-DAG) lipid
kinase activity (100~4)for each case. The ‘esults represent mean
±SD values of duplicate determinations and ate typical of tht’ee
experiments.
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sufficient for the inhibitory effect. The loci of CDP-
DAG and PA binding are unknown but do not appear
to be at the ATP- or P1-binding sites. On the basis
of findings in the analogous yeast protein VPS34, an
inferred lipid-binding site should be considered (see
Stephens et al., 1993).
The relevance of these observations to in vivo condi-
tions remains questionable. CDP-DAG is a quantita-
tively minor lipid; Thompson and Macdonald ( l976)
reported the presence of 13.2 prnol CDP-DAG/kg of
bovine brain. The present finding of an TCS() of 6 p.M
for inhibition of PT 3-kinase suggests that CDP-DAG
could well regulate this enzyme in vivo. Inhibition
would be further enhanced under conditions in which
intracellular CDP-DAG appears to be elevated. When
tissue slices (Godfrey, 1989) or cultured cells (Stubbs
and Agranoff, 1993) are pretreated with labeled cyti-
dine, and then with carbachol in the presence or ab-
sence of Li ~ labeled CDP-DAG is greatly increased,
presumably because PI-synthase activity has become
substrate limited for free inositol, on the basis of the
inhibition of inositol monophosphatase by Li + (Ber-
ridge et al., 1989). In the case of SH-SY5Y cells, the
increase is seen only if they have been deprived of
inositol in the incubation medium as well (Stubbs and
Agranoff, 1993). Although CDP-DAG mass has not
been measured in rat brain, I 3H ] cytidine-labeling stud-
ies in neurotransmitter-stimulated rat brain slices indi-
cate a heterogeneous distribution that is presumed to
indicate a broad range of amounts of the liponucleotide
among brain cell types as well (Hwang et al., 1990).
It is of interest that the concentration of’ CDP-DAG
in plasma membranes of inositol-starved Inol yeast
cells was found to be 12-fold higher than in inositol-
supplemented cells, and that this elevation was associ-
ated with inhibition of P1 4-kinase (Nickels et al.,
1994). Tt is not yet known whether mammalian P1 4-
kinase activity is affected by phospholipids. CDP-
DAG in eukaryotic cells appears to be compartmented
intracellulary in distinct mitochondrial and endoplas-
mic reticulum sites for the formation of cardiolipin and
phospoinositides, respectively (Mok et a!., 1992). On
the basis of the recent cloning of a Drosophila CDP-
DAG synthase (CDS) gene and identification of a de-
fective mutant (Wu et al., 1995), it appears that cell
types may vary in isoforms of CDS and thus could
also vary in levels of CDP-DAG under resting and
stimulated conditions. Although PA inhibits P1 3-ki-
nase with a somewhat higher IC
5~1(38 pM) than found
for CDP-DAG, it should be noted that PA is present
in 100-fold higher amounts than CDP-DAG in adult
rat brain, and increases with age from 14 p.M in 3-
day-old rats to 1.3—1.4mM in 330-day-old rat brains
(Wells and Dittmer, 1967). A similar value for PA
was found in bovine brain (Thompson and Macdonald,
1976). We have previously reported that SK-N-SH
cells, the parent line of the SH-SY5Y subclonc, contain
20 nmol PA/mg of protein (Lee et al., 1991), corre-
sponding to a calculated concentration of 20 pM, and
that carbachol more than doubles the PA concentration,
bringing it well within the range of the in vitro IC50
(38 pM) observed in this study. In addition, hormone-
induced generation of PA is reported to occur widely
via activation of phospholipase D or the sequential
activation of phospholipase C and DAG kinase (see
Liscovitch, 1992). It may then be concluded that un-
less intracellular compartmentation prevents access,
PA likely regulates P1 3-kinase in vivo.
These in vitro studies suggest that in vivo regulation
of P1 3-kinase activity by intracellular PA and/or by
CDP-DAG may underlie a functional relationship of
these metabolic precursors with the PI3P and PI4P
inositol lipids.
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